Drug Trial Radar · NCT05547906
Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Nov 8, 2021
Primary completion
Feb 29, 2024
Study completion Feb 29, 2024
Sponsor
- Lead sponsor
- MetaFinesIndustry
- Sponsor type
- Industry
- First posted
- Sep 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open-label, dose escalation Phase 1 study. The purpose of this study is to evaluate the following objectives in patients with advanced solid tumors after failure of standard of care.
Conditions
- Solid Tumor
Interventions
ASCA101Drug
IV infusion Twice a Week, 8 times per each Cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose(MTD)Time frame: 4weeks
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
California Research Institute
Los Angeles, California
Seoul national university bundang hospital
Seongnam-si, Gyeonggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.